Tokyo Tape
Sign in
← GNI Group

Half-year report · Q2

2160.TEDINET S100U8GV
Period2024-01-01 → 2024-06-30
Filed2024-08-14
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥11.7bn2024-01-01 → 2024-06-30Cons.Revenue IFRS
Revenue¥5.8bn2024-04-01 → 2024-06-30dCons.Revenue IFRS
Revenue¥26.0bn2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥14.1bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥9.9bn2023-04-01 → 2023-06-30dCons.Revenue IFRS
Operating income¥1.8bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Operating income−¥522m2024-04-01 → 2024-06-30dCons.Operating profit loss IFRS
Operating income¥5.5bn2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥5.1bn2023-04-01 → 2023-06-30dCons.Operating profit loss IFRS
Profit before tax¥831m2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥996m2024-04-01 → 2024-06-30dCons.Profit loss before tax IFRS
Profit before tax¥12.6bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥5.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥5.2bn2023-04-01 → 2023-06-30dCons.Profit loss before tax IFRS
Net income (owners)¥330m2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥1.1bn2024-04-01 → 2024-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥8.1bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.7bn2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.7bn2023-04-01 → 2023-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥74m2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Net income−¥1.4bn2024-04-01 → 2024-06-30dCons.Profit loss IFRS
Net income¥9.5bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥4.0bn2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Net income¥4.4bn2023-04-01 → 2023-06-30dCons.Profit loss IFRS
Total assets¥69.0bnat 2024-06-30Cons.Assets IFRS
Total assets¥62.4bnat 2023-12-31Cons.Assets IFRS
Total assets¥45.1bnat 2023-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥29.4bnat 2024-06-30Cons.Liabilities IFRS
Total liabilities¥26.3bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥39.6bnat 2024-06-30Cons.Equity IFRS
Net assets / equity¥36.1bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥24.8bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥19.8bnat 2022-12-31dCons.Equity IFRS
Equity (owners)¥36.8bnat 2024-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥33.8bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥23.0bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥16.3bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥21.6bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.1bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.0bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥6.5bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥872m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥5.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥6.8bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥2.6bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥186m2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥10.7bn2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥3.9bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥6.612024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-22.492024-04-01 → 2024-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥169.52023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥34.932023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥34.992023-04-01 → 2023-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥6.372024-01-01 → 2024-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-22.492024-04-01 → 2024-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥165.562023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥34.812023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥34.882023-04-01 → 2023-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio53.4%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio54.2%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio51.0%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2024-01-01 → 2024-06-30¥2.6bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2024-01-01 → 2024-06-30¥2.6bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2024-01-01 → 2024-06-30¥676m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2024-01-01 → 2024-06-30¥9.1bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2024-01-01 → 2024-06-30¥9.1bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2024-01-01 → 2024-06-30¥1.1bn
—segment totalrevenue2024-01-01 → 2024-06-30¥11.7bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥11.7bn
—segment totalsegment profit2024-01-01 → 2024-06-30¥1.8bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥23m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥23m
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2023-01-01 → 2023-06-30¥1.4bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2023-01-01 → 2023-06-30¥1.3bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥23m
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2023-01-01 → 2023-06-30¥512m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2023-01-01 → 2023-06-30¥12.8bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2023-01-01 → 2023-06-30¥12.8bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2023-01-01 → 2023-06-30¥5.0bn
—segment totalrevenue2023-01-01 → 2023-06-30¥14.1bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥14.1bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥23m
—segment totalsegment profit2023-01-01 → 2023-06-30¥5.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 740
ItemContextValueUnit
Issuance of share acquisition rights ss IFRSCurrentYTDDuration326000JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-74382000JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember－JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration-74382000JPY
Issuance cost of share acquisition rights ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-3998000JPY
Issuance cost of share acquisition rights ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember－JPY
Issuance cost of share acquisition rights ss IFRSCurrentYTDDuration-3998000JPY
Total transactions with owners IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-847287000JPY
Total transactions with owners IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember1080102000JPY
Total transactions with owners IFRSCurrentYTDDuration232814000JPY
Equity IFRSCurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember36834916000JPY
Equity IFRSCurrentQuarterInstant_NonControllingInterestsIFRSMember2729380000JPY
Equity IFRSCurrentQuarterInstant39564297000JPY
Profit loss before tax IFRSPrior1YTDDuration5117961000JPY
Profit loss before tax IFRSCurrentYTDDuration831391000JPY
Depreciation expense ope cf IFRSPrior1YTDDuration274252000JPY
Depreciation expense ope cf IFRSCurrentYTDDuration419755000JPY
Decrease increase in trade and other receivables ope cf IFRSPrior1YTDDuration-4060271000JPY
Decrease increase in trade and other receivables ope cf IFRSCurrentYTDDuration-657775000JPY
Increase decrease in trade and other payables ope cf IFRSPrior1YTDDuration-332147000JPY
Increase decrease in trade and other payables ope cf IFRSCurrentYTDDuration-97070000JPY
Decrease increase in inventories ope cf IFRSPrior1YTDDuration109315000JPY
Decrease increase in inventories ope cf IFRSCurrentYTDDuration-337943000JPY
Bonus allowance ope cf IFRSPrior1YTDDuration-26766000JPY
Bonus allowance ope cf IFRSCurrentYTDDuration-50713000JPY
Finance income and finance costs ope cf IFRSPrior1YTDDuration435807000JPY
Finance income and finance costs ope cf IFRSCurrentYTDDuration330181000JPY
Other changes in working capital ope cf IFRSPrior1YTDDuration228858000JPY
Other changes in working capital ope cf IFRSCurrentYTDDuration-412469000JPY
Subtotal ope cf IFRSPrior1YTDDuration1747009000JPY
Subtotal ope cf IFRSCurrentYTDDuration25356000JPY
Interest received ope cf IFRSPrior1YTDDuration52577000JPY
Interest received ope cf IFRSCurrentYTDDuration201543000JPY
Interest paid ope cf IFRSPrior1YTDDuration-10965000JPY
Interest paid ope cf IFRSCurrentYTDDuration-39488000JPY
Income taxes refund paid ope cf IFRSPrior1YTDDuration-916242000JPY
Income taxes refund paid ope cf IFRSCurrentYTDDuration-1655085000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration872378000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration-1467673000JPY
Net decrease increase in time deposits inv cf IFRSPrior1YTDDuration-1556800000JPY
Net decrease increase in time deposits inv cf IFRSCurrentYTDDuration-1253523000JPY
Purchase of property plant and equipment inv cf IFRSPrior1YTDDuration-601480000JPY
Purchase of property plant and equipment inv cf IFRSCurrentYTDDuration-304800000JPY
Purchase of intangible assets inv cf IFRSPrior1YTDDuration-425754000JPY
Purchase of intangible assets inv cf IFRSCurrentYTDDuration-414750000JPY
Purchase of investment securities inv cf IFRSPrior1YTDDuration－JPY
Purchase of investment securities inv cf IFRSCurrentYTDDuration-1025672000JPY
Proceeds from sale of investment securities inv cf IFRSPrior1YTDDuration－JPY
Proceeds from sale of investment securities inv cf IFRSCurrentYTDDuration191560000JPY
Increase of leasehold and guarantee deposits inv cf IFRSPrior1YTDDuration-3625000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass